To cite this paper use one of the standards below:
1. Introduction
Epilepsy is a neurological condition characterized by recurrent seizures affecting 50 million people worldwide, with a high prevalence of pharmacoresistance, especially in temporal in lobe epilepsy (TLE). TLE is associated with hippocampal sclerosis, characterized by neuronal loss in hippocampal regions CA1 and CA3 and severe astrogliosis. Neurovespina, a peptide bioinspired by the venom of the social wasp Polybia occidentalis, has shown antiepileptic and neuroprotective properties. Nanoencapsulation of neurovespina enhances its bioavailability, bypasses physiological barriers, and enables efficient intranasal administration.
2. Methodology
Using a chronic TLE model induced by pilocarpine (150 mg/kg, i.p.), following Ethical Principles in Animal Experimentation, male Swiss mice (n=6-8/group) were treated during the chronic period (15th to 30th day) with free neurovespina (4 mg/kg, s.c.), nanoencapsulated neurovespina (NanoNE, 20 µg, i.n.), NanoBranco (20 µg, i.n.), diazepam (4 mg/kg, s.c.), or saline (4 mg/kg, s.c.). Hippocampi were histologically analyzed using Nissl staining to evaluate neuronal cytoarchitecture alterations in the CA1, CA3, and dentate gyrus (DG) regions.
3. Results
Free Neurovespina exhibited significant neuroprotective effects in CA1 and the dentate gyrus, reducing neuronal damage compared to untreated epileptic controls. NanoNeurovespina further enhanced these effects, particularly in CA3 and the dentate gyrus, indicating improved efficacy through nanoencapsulation. The nanoparticle formulation improved drug stability, bioavailability, and targeted delivery to the hippocampal regions.
4. Conclusion
Neurovespina, particularly in its nanoencapsulated form, shows potential as an innovative TLE treatment. By reducing neurodegeneration and controlling seizures, it is a promising candidate for future therapies targeting neurodegenerative diseases. Future research should optimize dosing, refine administration intervals, and explore broader clinical applications.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper